BiotechTube

GSK4527226

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease

Trial Timeline

Aug 14, 2025 → Dec 8, 2028

NCT ID
NCT07105709

About GSK4527226

GSK4527226 is a phase 2 stage product being developed by Alector for Alzheimer's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07105709. Target conditions include Alzheimer's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT07105709Phase 2Recruiting
NCT06079190Phase 2Active

Competing Products

20 competing products in Alzheimer's Disease

See all competitors
ProductCompanyStageHype Score
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
simufilamCassava SciencesPhase 2
44
Remternetug + PlaceboEli LillyPhase 3
77
solanezumabEli LillyPhase 2
52
LY2886721 + PlaceboEli LillyPhase 1
33
Gantenerumab + Gantenerumab + Gantenerumab + PlaceboChugai PharmaceuticalPhase 1
33
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
85
FK962Astellas PharmaPhase 2
52
ASP0777 + PlaceboAstellas PharmaPhase 1
33
Elenbecestat + PlaceboEisaiPhase 3
77
DonepezilEisaiApproved
85
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)EisaiPhase 3
77
Donepezil hydrochlorideEisaiPhase 3
77
Donepezil HydrochlorideEisaiPre-clinical
23
Lecanemab IV + Placebo + Lecanemab SCEisaiPhase 3
77

Other Products from Alector

AL001 + Placebo + Open label - AL001Phase 3
69
LatozinemabPhase 3
69
GSK4527226Phase 2
44
AL001 + PlaceboPhase 2
44
AL002Phase 2
44